Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor

The use of antiplatelet agents, specifically the thienopyridines, has become a standard of care in the approach to the patient presenting with an acute coronary syndrome. These drugs irreversibly inhibit the platelet by permanently binding to the surface P2Y12 receptor and blocking the downstream fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Birkeland, Kade, Parra, David, Rosenstein, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262315/
https://www.ncbi.nlm.nih.gov/pubmed/22282698
http://dx.doi.org/10.2147/JBM.S9650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262315/
https://www.ncbi.nlm.nih.gov/pubmed/22282698
http://dx.doi.org/10.2147/JBM.S9650

Ejemplares similares